Investor & Analyst Day 2015: Cologuard Expansion (4/8)
5
-
Upload
exact-sciences -
Category
Investor Relations
-
view
582 -
download
1
Transcript of Investor & Analyst Day 2015: Cologuard Expansion (4/8)
![Page 1: Investor & Analyst Day 2015: Cologuard Expansion (4/8)](https://reader035.fdocuments.in/reader035/viewer/2022071903/55c52df6bb61eb66638b466f/html5/thumbnails/1.jpg)
![Page 2: Investor & Analyst Day 2015: Cologuard Expansion (4/8)](https://reader035.fdocuments.in/reader035/viewer/2022071903/55c52df6bb61eb66638b466f/html5/thumbnails/2.jpg)
vCologuard® Expansion
![Page 3: Investor & Analyst Day 2015: Cologuard Expansion (4/8)](https://reader035.fdocuments.in/reader035/viewer/2022071903/55c52df6bb61eb66638b466f/html5/thumbnails/3.jpg)
3
The information and data presented here was prepared for investors and potential investors. It includes forward-looking information on investigational products in development that are not available for sale in the United States. These include early-stage development products for which the performance characteristics have not yet been established.
![Page 4: Investor & Analyst Day 2015: Cologuard Expansion (4/8)](https://reader035.fdocuments.in/reader035/viewer/2022071903/55c52df6bb61eb66638b466f/html5/thumbnails/4.jpg)
Multiple opportunities to expand Cologuard® use
• Evaluating broader US screening populations
– High-risk individuals (20M Americans)
– 40-49 year olds (40M Americans)
• Addressing these markets requires
– Clinical and pharmacoeconomic data
– Guideline committees support
– Regulatory support
![Page 5: Investor & Analyst Day 2015: Cologuard Expansion (4/8)](https://reader035.fdocuments.in/reader035/viewer/2022071903/55c52df6bb61eb66638b466f/html5/thumbnails/5.jpg)